

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

**RANBAXY ANNOUNCES CONCLUSION OF PREVIOUSLY DISCLOSED  
INVESTIGATION BY U.S. DEPARTMENT OF JUSTICE**

**Tokyo, Japan (May 14, 2013)** –Attached is the press release by Ranbaxy Laboratories Ltd., a subsidiary of Daiichi Sankyo Co., Ltd., which was issued on May 13, 2013.

# RANBAXY

FOR IMMEDIATE RELEASE

## RANBAXY ANNOUNCES CONCLUSION OF PREVIOUSLY DISCLOSED INVESTIGATION BY U.S. DEPARTMENT OF JUSTICE

**Gurgaon, India – May 13, 2013** -- Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), today announced that a previously disclosed investigation by the U.S. Department of Justice (“DOJ”) of data integrity and manufacturing processes at certain Ranbaxy facilities in India has been concluded. The investigation related to conduct which occurred several years ago, and Ranbaxy’s current management team fully cooperated with the DOJ.

On December 20, 2011, Ranbaxy announced that it had signed a consent decree with the U.S. Food and Drug Administration (“USFDA”), under which Ranbaxy committed to further strengthen procedures and policies to ensure data integrity and to comply with Current Good Manufacturing Practice (“cGMP”). In anticipation of the settlement agreement with the DOJ announced today, Ranbaxy announced at that time its intention to make a financial provision of \$500 million related to expected costs associated with resolving the DOJ investigation.

Under the terms of the final settlement agreement, Ranbaxy and its affiliates have agreed to settle alleged civil violations of the False Claims Act with the U.S., all 50 states and the District of Columbia. Separately, a U.S. subsidiary, Ranbaxy USA, Inc., has agreed to plead guilty to a criminal information charging violations of the Food, Drug and Cosmetic

Act and other criminal statutes. Ranbaxy's payments related to both the civil and criminal settlements total \$500 million in aggregate. The financial provision Ranbaxy established in December 2011 will be sufficient to cover all material financial obligations under the agreement.

Mr. Arun Sawhney, CEO & Managing Director, Ranbaxy, stated, "Today's announcement marks the resolution of this past issue. We are pleased to continue bringing safe, effective and quality medicines to market for the benefit of consumers in the U.S. and other parts of the world. While we are disappointed by the conduct of the past that led to this investigation, we strongly believe that settling this matter now is in the best interest of all of Ranbaxy's stakeholders; the conclusion of the DOJ investigation does not materially impact our current financial situation or performance. Ranbaxy has successfully launched several generic products recently and is well-positioned for future growth in the U.S. and around the world with a robust pipeline of important products as it continues to build a strong global portfolio of branded and generic prescription and OTC pharmaceuticals. Our conduct is guided by our philosophy of 'Quality and Patients First.'"

#### About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more

complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit [www.ranbaxy.com](http://www.ranbaxy.com).

**CONTACTS:**

**Koji Ogawa**

Head - Corporate Services  
Ranbaxy Laboratories Limited  
Gurgaon  
email: [koji.ogawa@ranbaxy.com](mailto:koji.ogawa@ranbaxy.com)  
Tel: +91-124-4135620

**Krishnan Ramalingam**

General Manager, Corporate Communications  
Ranbaxy Laboratories Limited  
Gurgaon  
email: [krishnan.ramalingam@ranbaxy.com](mailto:krishnan.ramalingam@ranbaxy.com)  
Mobile: 9810042540

**Chuck Caprariello**

Vice President, Communications  
Ph: 609-720-5615  
E-mail: [Chuck.caprariello@ranbaxy.com](mailto:Chuck.caprariello@ranbaxy.com)

**David Reno/Trevor Rees**

Sard Verbinnen & Co.  
Ph: (212) 687-8080  
E-mail: [Trees@sardverb.com](mailto:Trees@sardverb.com)